Inhibiton Therapeutics’s cancer drug found effective in in-vitro testing

The present work performed under a co-operative research and development agreement with the department of veteran’s affairs demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.

Laboratory testing to date has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells. It was also found that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64% and 53% of the neuroblastoma cells when compared to control groups.

The effective concentration of ICA-1 was shown to be a minimum of 3-5 fold lower than concentrations in-vitro conditions of a closely related FDA approved chemotherapeutic drug that was shown to be effective in only 20% of the samples tested. The results to date have shown promise that ICA-1 may have potential as a chemotherapeutic drug to inhibit cancer, especially neuroblastoma.

The company’s research is being performed at the James A. Haley Veterans’s Hospital in Tampa, Florida, in conjunction with the University of South Florida.